• enGene filed an amended 8-K to update restructuring charges tied to its June 14 plan to cut about 50% of its workforce.
• Added performance-based equity retention awards, lifting expected non-cash stock-based compensation tied to the restructuring to USD 4.7 million-USD 5 million.
• Projected restructuring cash costs unchanged at USD 5.7 million-USD 6.4 million, mainly severance and benefits; most charges still expected in 2H 2026.
• Estimated retention costs now include up to USD 1.7 million cash, up to USD 2.8 million non-cash compensation linked to milestone-based vesting.
• CEO Ronald Cooper received a 400,000-share performance-based option at USD 1.75, vesting on BLA acceptance by Sep. 30, 2027 and FDA approval by Dec. 31, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-275815), on June 18, 2026, and is solely responsible for the information contained therein.